We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Genetic Mutations Linked to Subset of Gastrointestinal Stromal Tumors

By LabMedica International staff writers
Posted on 27 Dec 2016
Researchers have identified new gene fusions and mutations associated with a subset of Gastrointestinal Stromal Tumors (GIST) patients who lack the documented tell-tale mutations, making diagnosis and treatment more difficult in these cases.

“We are continuing to slice the GIST pie into thinner pieces based upon identifying new driver genes,” said study leader Jason Sicklick, MD, associate professor at University of Californai San Diego School of Medicine (La Jolla, CA, USA) and surgical oncologist at Moores Cancer Center at UCSD Health (La Jolla, CA, USA), “This will allow for a more personalized approach to treating GIST patients.” In addition to researchers at UCSD, the study team included collaborators from other USA states and from South Korea.

Prof. More...
Sicklick and colleagues are leading efforts to diagnose and treat GIST, which originates in special cells that signal muscles to contract, moving food and liquid through the digestive system. Many current therapies for GIST are ineffective in patients (About 10–15% of adult and most pediatric cases) whose tumors lack mutations in the classic oncogenic drivers of GIST. Ultimately, over 95% of patients eventually succumb to drug-resistant GIST, highlighting the necessity for alternative therapeutic targets.

Treatment with imatinib (marketed as Gleevec) has proven effective in many GIST cases associated with KIT oncogene mutations, the most common driver of the disease. Building upon that success and approach, the research team used broad genomic sequencing of GIST patients without KIT – or other documented mutations – to identify alterations in at least two new genes: FGFR1 and NTRK3.

“Broad genomic sequencing was critical to expand our search beyond the KIT mutations streetlight,” said Olivier Harismendy, PhD, head of the oncogenomics laboratory at Moores Cancer Center, referring to observational bias of previous studies.

“These findings provide novel insights into the biology of the disease and new potential genetic drivers,” said Prof. Sicklick, “With further studies, we can build an even more complete genetic profile of GIST, which in turn can lead to new individualized treatments and better outcomes for more GIST patients. For example, one patient in this study had an ETV6-NTRK3 mutant GIST and responded to a matched therapy with Loxo-101, a highly selective TRK inhibitor, after progressing on several earlier lines of FDA-approved therapies for GIST.

The study, by Shi E et al, was published December 14, 2016, in the Journal of Translational Medicine.

Related Links:
University of Californai San Diego School of Medicine
Moores Cancer Center at UCSD Health

New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Blood Glucose Test Strip
AutoSense Test
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Microbiology

view channel
Image: The groundbreaking salmonella antimicrobial resistance prediction platform has demonstrated 95% accuracy (Photo courtesy of Yujie You et al., DOI: 10.1016/j.eng.2025.01.013)

New Platform Leverages AI and Quantum Computing to Predict Salmonella Antimicrobial Resistance

Antimicrobial-resistant Salmonella strains are a growing public health concern due to the overuse of antimicrobials and the rise of genetic mutations. Accurate prediction of resistance is crucial for effective... Read more

Technology

view channel
Image: The Check4 gene-detection platform (Photo courtesy of IdentifySensors)

Electronic Biosensors Used to Detect Pathogens Can Rapidly Detect Cancer Cells

A major challenge in healthcare is the early and affordable detection of serious diseases such as cancer. Early diagnosis remains difficult due to the complexity of identifying specific genetic markers... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.